Vertex Pharmaceuticals Incorporated (VRTX)
VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study
Vertex stock jumps after interim phase III data show povetacicept cuts proteinuria 52% in IgA nephropathy study and boost hopes for accelerated FDA approval.
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Vertex Q4 earnings miss estimates, but revenues top forecasts on strong CF sales and momentum from new launches like Alyftrek, Casgevy and Journavx.
Vertex (VRTX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Vertex Pharmaceuticals (VRTX) Q4 Earnings Miss Estimates
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $5.03 per share, missing the Zacks Consensus Estimate of $5.07 per share. This compares to earnings of $3.98 per share a year ago.
Why Vertex Pharmaceuticals (VRTX) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Seeking Clues to Vertex (VRTX) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Vertex (VRTX) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
